StreetInsider.com News Articles

Opko Health stock soars on $722M BioReference asset sale

Thu, 15 Oct 2026 09:53:22 -0400

Investing.com -- Opko Health Inc (NASDAQ:OPK) shares surged 20% in premarket trading Thursday after Labcorp Holdings Inc (NYSE:LH) agreed to acquire select assets of BioReference Health for $722 million in cash.

Labcorp will acquire BioReference Health's laboratory testing businesses focused on clinical and women's health testing services, urology, corrections and certain operational assets, including over 80 patient service centers. The purchase price includes up to an additional $150 million in an earnout based on revenue from the 4Kscore Test.

The transaction includes BioReference Health's proprietary 4Kscore Test, an FDA-approved blood test that helps predict the likelihood

Opko Health stock soars on $722M BioReference asset sale

Thu, 15 Oct 2026 09:53:22 -0400

The transaction includes BioReference Health's proprietary 4Kscore Test, an FDA-approved blood test that helps predict the likelihood

Opko Health stock soars on $722M BioReference asset sale

Thu, 15 Oct 2026 09:53:22 -0400

The transaction includes BioReference Health's proprietary 4Kscore Test, an FDA-approved blood test that helps predict the likelihood

Opko Health stock soars on $722M BioReference asset sale

Thu, 15 Oct 2026 09:53:22 -0400

The transaction includes BioReference Health's proprietary 4Kscore Test, an FDA-approved blood test that helps predict the likelihood

Labcorp to buy BioReference Health assets from OPKO for $722M

Thu, 15 Oct 2026 07:30:44 -0400

Labcorp (NYSE: LH) has agreed to acquire select assets of BioReference Health, LLC, a wholly owned subsidiary of OPKO Health (Nasdaq: OPK), for $722 million in cash at closing, with up to an additional $150 million in an earnout tied to revenue from the 4Kscore Test.

Under the terms of the deal, Labcorp will acquire BioReference Health's clinical and women's health testing businesses, urology, corrections services, and certain operational assets, including more than 80 patient service centers. The transaction also includes BioReference Health's proprietary 4Kscore Test, an FDA-approved blood test used to assess the likelihood of aggressive prostate cancer prior to

Labcorp to buy BioReference Health assets from OPKO for $722M

Thu, 15 Oct 2026 07:30:44 -0400

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Thu, 15 Oct 2026 07:30:00 -0400

Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide

BURLINGTON, N.C. and MIAMI, Fla., Oct. 15, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK),

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Thu, 15 Oct 2026 07:30:00 -0400

Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide

BURLINGTON, N.C. and MIAMI, Fla., Oct. 15, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK),

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Thu, 15 Oct 2026 07:30:00 -0400

Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide

BURLINGTON, N.C. and MIAMI, Fla., Oct. 15, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK),

Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

Thu, 15 Oct 2026 07:30:00 -0400

Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide

BURLINGTON, N.C. and MIAMI, Fla., Oct. 15, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK),

Labcorp and Arianna Huffington's Thrive Global Collaborate to Launch Thrive 5 Health Test

Tue, 13 Oct 2026 08:00:00 -0400

First lab test offered in collaboration with Thrive Global
Combines Labcorp's scientific expertise with Thrive Global's behavior change approach to help consumers turn health insights into healthier daily habits

Labcorp and Arianna Huffington's Thrive Global Collaborate to Launch Thrive 5 Health Test

Tue, 13 Oct 2026 08:00:00 -0400

First lab test offered in collaboration with Thrive Global
Combines Labcorp's scientific expertise with Thrive Global's behavior change approach to help consumers turn health insights into healthier daily habits

Form 8-K LABCORP HOLDINGS INC. For: Sep 30

Wed, 30 Sep 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260930/27125864.html

Labcorp to Announce Third Quarter 2026 Financial Results on October 28, 2026

Wed, 30 Sep 2026 08:30:00 -0400

BURLINGTON, N.C., Sept. 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2026 before the market opens on Wednesday, October 28, 2026. The company will host a webcast beginning at 9:00 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the "News

Labcorp to Announce Third Quarter 2026 Financial Results on October 28, 2026

Wed, 30 Sep 2026 08:30:00 -0400

Form 8-K LABCORP HOLDINGS INC. For: Sep 22

Tue, 22 Sep 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260922/27091558.html

Mizuho comments on DGX and LH post CMS on Monday

Tue, 22 Sep 2026 09:19:38 -0400

Mizuho comments on DGX and LH post CMS on Monday.

The analyst comments "After the close yesterday, the Centers for Medicare and Medicaid Services (CMS) released preliminary Calendar Year (CY) 2027 Clinical Laboratory Fee Schedule (CLFS) payment rates under the Protecting Access to Medicare Act (PAMA), the first repricing since 2018. The average potential change to CY2026 rates is ~16% lower. Cuts are broadly concentrated in esoteric testing while Proprietary Laboratory Analysis is relatively insulated at -2.4%. Final rates are expected to be released in November. We would note that LH's adjusted EPS CAGR of +8.5%-11.5% provided at the 2026 Investor

Mizuho comments on DGX and LH post CMS on Monday

Tue, 22 Sep 2026 09:19:38 -0400

Mizuho comments on DGX and LH post CMS on Monday.

Mizuho comments on DGX and LH post CMS on Monday

Tue, 22 Sep 2026 09:19:38 -0400

Mizuho comments on DGX and LH post CMS on Monday.

Mizuho comments on DGX and LH post CMS on Monday

Tue, 22 Sep 2026 09:19:38 -0400

Mizuho comments on DGX and LH post CMS on Monday.

Laboratory Corporation of America (LH) PT Raised to $361 at Baird

Tue, 22 Sep 2026 07:23:43 -0400

Baird analyst Eric Coldwell raised the price target on Laboratory Corporation of America (NYSE: LH) to $361.00 (from $352.00) while maintaining a Outperform rating.

Evercore comments on LH and DGX post CMS on Monday

Tue, 22 Sep 2026 06:29:53 -0400

Evercore comments on LH and DGX post CMS on Monday.

The analyst comments "What Happened? CMS released preliminary CY2027 CLFS rates today, based on the second PAMA private-payor rate survey. Based on the survey, CMS’s preliminary numbers note that Medicare has been paying ~16% more than private payors for lab services. PAMA has a maximum price cut of 15% on any single code's cut, which is to start January 1, 2027 and be phased in through 2029. These are preliminary rates and we now enter into a 30-day of comment period before final rates are expected in November. Our Take: Today’s